Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced initiation of patient dosing in its PHYOX™4 clinical trial to assess nedosiran for the treatment of primary hyperoxaluria type 3.

Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14.

Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.

Dicerna Announces Novo Nordisk's Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria.

Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria

Investors need to pay close attention to Dicerna (DRNA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Dicerna (DRNA) Stock?

Dicerna is right behind Alnylam in the RNAi space. Its lead candidate is nedosiran targeting primary hyperoxaluria.

Dicerna: Great Value RNAi Runner Up

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).

Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD's The Liver Meeting® Digital Experience™ 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration.

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies' Global Research Collaboration and Licensing Agreement

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present an update on the Company's early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020.

Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns rather than following the ups and downs of equity markets hoping that they will outperform the broader market. Our research shows that certain hedge funds do have great stock picking skills (and we can identify these hedge funds in advance pretty accurately), so let's take a glance at the smart money sentiment towards Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)?

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2020 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020.

Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020.

Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD's The Liver Meeting® Digital Experience™ 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5.

Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Dicerna Pharmaceuticals (DRNA) Report Negative Q3 Earnings? What You Should Know

Blueprint Medicines

AnaptysBio

uniQure

Spero Therapeutics

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in biotech research and investments, which included 15 years working at Mark Lampert's Biotechnology Value Fund, to seek out mispriced small-cap companies in the biotech sector. The fund's assets under management surpassed $500 million as of August 2020.

5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3.

Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20.

Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that clinical data on nedosiran, an investigational candidate for the treatment of PH, will be presented at ASN Kidney Week 2020.

Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Mon., Oct. 5, 2020 at 1:30 p.m. ET.

Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the hiring of Ling Zeng, Esq.

Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary

Dicerna develops RNAi therapies. Several large-cap pharma companies are collaborators.

Dicerna Pharmaceuticals May Be The Best Value Among RNAi Companies

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will be participating in four virtual investor conferences in September.

Dicerna to Participate in Upcoming September Investor Conferences

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q2 2020 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues

Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues

News for Dicerna Pharmaceuticals Stock (DRNA)